Use of a sodium--glucose cotransporter 2 inhibitor, empagliflozin, in a
patient with Rabson-Mendehall Syndrome
Rabson-Mendenhall Syndrome (RMS) is a rare condition caused by mutations
in the insulin receptor gene. The affected patients have severe insulin
resistance and the treatment is challenging due to difficulties in
reaching satisfactory glycemic control. We report a case where iSGT2 was
used as an adjunct therapy to insulin.